Chi-Med’s Elunate® (Fruquintinib Capsules) Included in the National Reimbursement Drug List in China

LONDON, Nov. 28, 2019 (GLOBE NEWSWIRE) — Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) today announces that Elunate^® (fruquintinib capsules), its national class 1 targeted anticancer drug for the treatment of patients with advanced colorectal cancer (“CRC”), has been included in the updated National Reimbursement Drug List (“NRDL”) released by China’s National Healthcare Security Administration (“NHSA”). 
“Elunate^® is Chi-Med’s first novel oncology drug commercially launched in China,” commented Mr. Christian Hogg, Chief Executive Officer of Chi-Med.  “The inclusion in the NRDL is a very important step forward to broaden availability and patient access to Elunate^® across China.  We now look forward to our partner, Eli Lilly and Company (“Lilly”), to capitalize on the opportunity provided by this important government policy to accelerate the accessibility of Elunate^® to patients across China.”Dr. Yizhe Wang, Senior VP of Lilly China and Head of Oncology and Bio-medicines, said, “We are very glad to see Elunate^® included in the NRDL, and we want to thank the medical experts involved in the selection process for their support.  Elunate^® is a new treatment option for patients with advanced colorectal cancer, and has helped several thousand patients since its launch.  We believe that this will further improve its affordability, help patients reduce their economic burden and improve their lives.”About the National Reimbursement Drug List (NRDL)